1999年 · 第112卷第10期

Prupose To highlight the development and achievements of hemostasis and thrombosis research in China over the past 50 years. Data sources Both Chinese and English language literature search using MEDLINE (1990-1998), and original articles published in the main Chinese and international journals. Study selection After reviewing all the main articles on thrombosis and hemostasis, 20 of them were selected that specifically addressed the stated purpose. Date Extration The content that could present the progress in hemostasis and thrombosis in China was selected. Results Monoclonal antibodies have widely been used in basic research and laboratory diagnosis. Several novel gene mutations of coagulation factors have been identified. Some drugs of traditional Chinese medicine have proved to be efficient in treatment of thrombotic diseases. Conclusions Significant achievements in basic, clinical and pharmacological research in the field of hemostasis and thrombosis have been made in China in the past 50 years. Some new discoveries in platelet membrane glycoproteins and coagulation factors research are believed to be contributions to the international scientific community. However, a specific effort using advanced techniques should be made for future development, especially in molecular biology research.

OBJECTIVE To summarize the progress of surgical treatment of hepatocellular carcinoma (HCC) and related basic research at the Liver Cancer Institute of Shanghai Medical University in the recent years, with special reference to recurrence and metastasis. METHODS Published and unpublished update clinical and experimental data in the above-mentioned areas are summarized. RESULTS Surgical resection has played an important role in improving prognosis of HCC, the 5-year survival were 63.4% for small HCC resection (n = 806), 39.6% for large HCC resection (n = 1061), 64.7% for cytoreduction (using hepatic artery cannulation and ligation) and sequential resection of initially unresectable HCC (n = 93), 56.0% for cytoreduction using transcatheter arterial chemoembolization (TACE) and followed by resection (n = 65), and 22.4% for hepatic resection with removal of tumor thrombi in portal vein (n = 103). Unfortunately, the 5-year recurrent rate after curative resection of HCC was up to 61.5%, which was mainly a result of intrahepatic "metastasis“ and multicentric origin of HCC. Clinically, re-resection of subclinical recurrence yielded 56% of 5-year survival (n = 202); prevention of recurrence by transcatheter arterial chemoembolization (TACE) + Interferon, or LAK/IL-2 therapy have decreased 3-year recurrent rate from 33% to 11%-18%. In experimental aspect, metastatic human HCC model in nude mice (LCI-D20) and HCC cell line with metastatic potential (MHCC97) have been established; studies on HCC invasiveness in the molecular level revealed similar results that reported in other solid cancers, and small HCC showed slightly better biological characteristics as compared with large HCC; microvessel density (MVD) that reflecting angiogenesis adversely correlated with 5-year survival of small HCC; experimental interventions using antisense H-ras, bispecific antibody, BB94, as well as anti-angiogenic agents (TNP470, suramin, CAI, heparin, antisense VEGF, etc.) have been demonstrated to inhibit tumor growth and lung metastasis in nude mice model. CONCLUSIONS Recurrence and metastasis are the major obstacle to further improve prognosis of HCC, studies should be conducted both in clinical and experimental aspects, "HCC invasiveness" will be the major target to be studied, particularly in the molecular level, and anti-angiogenesis will be one of the important approach.